{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 376,
  "pageCount": 415,
  "prevPage": 375,
  "nextPage": 377,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses Q&A transcripts to undermine the value proposition of the company's product.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/376",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-376",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.4
      },
      "kind": "callout",
      "text": "Highly receptive to PK equivalence and substitutability of generic diazoxide suspension",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5c954c3-f9ea-40eb-bbac-a4873110e15d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "“You’re absolutely right. I’m not a PK person, but if you’re telling me that there’s a similarity, it would make no sense to do it in a tablet — if you’re saying that the PK data is similar…you’re absolutely right.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b5-a1bbd7c8bff9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "When we indicated that the suspension has a long life and therefore could replicate the once-daily dosing of a table, he stated: “is the suggestion now that we don’t need them dose them 2 or 3 times a day [with suspension as is the convention for infant hyperinsulinism]?...listen, you’re absolutely right”; “You’re absolutely right...I’m not a PK person, but if you’re telling me that there’s a similarity, it would make no sense to do it in a tablet — if you’re saying that the PK data is similar...you’re absolutely right...”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11c66dd3-8b7f-43e6-a496-b141733babfa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "We highlighted that one of Soleno’s biggest risks is that physicians simply substitute generic diazoxide suspension in place of Vykat, to which the endocrinologist replied: “this is not good...this is not good at all” and shared his pre-existing concern of giving tablets to patients with developmental delays.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d13620d-f864-48d9-a875-87a0adc6c3c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "Q: “It seems to me that the biggest risk for this company is that one person gives a talk at the annual conference, raising these issues, and it could spread like wildfire. It’s a very small space.”\nA: “This is not good. This is not good at all.”\nQ: “If one pharmacology expert gets up and says, here's the PK curve, here's the data manipulation in the Soleno paper, here's a formula for the oral equivalent dose —.”\nA: “But clinically, we've been dosing these patients, the hypoglycemic patients, we've been dosing them two, three times a day. Historically, that's what we're doing. Basically, is the suggestion now that we don't need to dose them 2 or 3 times a day?”\nQ: “Diazoxide has a long half-life. It's not like you need to be dosing them all day long.”\nA: “But historically, we've done it 2 to 3 times. I think I'm going to rely on that data. But listen, you're absolutely right.” – Division Chief for pediatric endocrinology at a major NE academic center",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e877978-5de2-4307-a960-8f7787ce4dee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.71
      },
      "kind": "paragraph",
      "text": "“Absolutely right” that generic liquid makes more sense; already concerned about tablet formulation in PWS patients\n“You’re absolutely right. I’m not a PK person, but if you’re telling me that there’s a similarity, it would make no sense to do it in a tablet — if you’re saying that the PK data is similar. You’re absolutely right. Has that been an issue, a question that I brought up? Yes, it has been a question because you are giving, sometimes, developmentally delayed individuals, trying to get them to take this medication. And that’s certainly a concern.” – Division Chief for pediatric endocrinology at a major NE academic center",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc5e4997-3ac2-42a3-96ff-0eaffdcd3a89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“This is not good...this is not good at all” — Division Chief for pediatric endocrinology at a major NE academic center. “You’re absolutely right. I’m not a PK person, but if you’re telling me that there’s a similarity, it would make no sense to do it in a tablet — if you’re saying that the PK data is similar…you’re absolutely right.” — Division Chief for pediatric endocrinology at a major NE academic center.",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b5-a4c90ad82565",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b5ee0d9-58b8-455b-8eeb-469dc07ba587",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}